Table 1. Correlations between the clinicopathologic characteristics and dyskerin protein expression in hepatocellular carcinoma.

Characteristics	N	Dyskerin (%)		P *
		Negative/low expression	High expression
Gender				0.55
Male	209	88 (42.1)	121 (57.9)
Female	43	16 (37.2)	27 (62.8)
Age (years)				0.36
<60	176	78 (44.3)	98 (55.7)
> = 60	76	29 (38.2)	47 (61.8)
HbsAg				0.00
Negative	111	70 (63.1)	41 (36.9)
Positive	141	58 (43.1)	83 (58.9)
AFP (ng/ml)				0.00
<400	153	20 (32.0)	104 (68.0)
> = 400	99	52 (52.5)	47 (47.5)
Tumor size (cm) & §				0.81
<5	47	20 (42.6)	27 (57.4)
> = 5	94	42 (44.7)	52 (55.3)
Liver cirrhosis §				0.35
Absent	60	26 (44.3)	34 (56.7)
Mild	51	25 (49.1)	26 (50.9)
Moderate	54	22 (40.7)	32 (59.3)
Severe	31	9 (29.0)	22 (71.0)
Clinical stage §				0.00
I–II	185	102 (55.1)	83 (44.9)
III–IV	79	24 (30.4)	55 (69.6)
Adjacent organs invasion §				0.27
Negative	153	78 (51.0)	75 (49.0)
Positive	74	32 (43.2)	42 (56.8)
Reccurrence or metastasis §				0.66
Negative	148	57 (38.5)	91 (61.5)
Positive	76	27 (35.5)	49 (64.5)
Tumor encapsulation §				0.26
Absent	114	48 (42.1)	66 (57.9)
Present	109	38 (34.9)	71 (65.1)

AFP, alpha-fetoprotein; HbsAg, hepatitis B surface antigen.

^*: Two-tailed chi-Square test. 0.00 indicates <0.01.

&: Tumor size was measured based on the length of the largest tumor nodule.

^§: Some data were not available, and the statistical analysis was based on the available data.